Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + nab-paclitaxel with or without tocilizumab in first-line treatment of advanced pancreatic cancer
2016-000643-13Phase 2Completed
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of tocilizumab in pancreatic cancer (PC) (2 arms), sponsored by Herlev & Gentofte Hospital. Primary endpoint: Overall survival at 6 months. Started Jul 2016; status: completed.
02
Drugs
tocilizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2016-000643-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000643-13.